Lexicon Pharmaceuticals (LXRX) Change in Receivables (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Change in Receivables of $9.4 million for Q1 2026, up 1015.69% year-over-year from $842078.3 in Q1 2025, and up 18690.0% quarter-over-quarter from $50000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Change in Receivables (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Change in Receivables for 17 consecutive years, with $9.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 1015.69% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $9.3 million (up 913.25% YoY), while the FY2025 annual figure was -$1.1 million, down 144.21% from the prior year.
- Change in Receivables rose to $9.4 million in Q1 2026 per LXRX's latest filing, from $50000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $9.4 million in Q1 2026 and bottomed at -$1.0 million in Q1 2025.
- Historically, Change in Receivables has averaged $692058.8 across 5 years, with a median of $151000.0 in 2025.
- On a YoY basis, Change in Receivables climbed as much as 14200.0% in 2023 and fell as far as 6216.67% in 2023.
- Lexicon Pharmaceuticals' Change in Receivables stood at -$12000.0 in 2022, then jumped by 5866.67% to $692000.0 in 2023, then dropped by 16.47% to $578000.0 in 2024, then plunged by 91.35% to $50000.0 in 2025, then soared by 18690.0% to $9.4 million in 2026.
- Business Quant data shows LXRX's Change in Receivables at $9.4 million in Q1 2026, $50000.0 in Q4 2025, and $151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.14 Mn |
| Jun 30, 2026 | -10.14 Mn |
| Mar 31, 2026 | 9.40 Mn |
| Mar 31, 2026 | 9.40 Mn |
| Dec 31, 2025 | 50,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Mar 31, 2025 | -1.03 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | 578,000.00 |
| Dec 31, 2024 | 578,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 516,000.00 |
| Mar 31, 2024 | 516,000.00 |